<DOC>
	<DOCNO>NCT01273896</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , STA-9090 patient breast cancer . STA-9090 experimental drug work break cancer protein . When cancer proteins destroy , cancer cell die . STA-9090 experimental drug yet approve treatment cancer United States ( FDA ) Food Drug Administration . STA-9090 test cancer patient trial safe dose drug find . We interested see active drug breast cancer .</brief_summary>
	<brief_title>Open-label Study STA-9090 Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Male Female patient must least 18 year age Pathologically confirm diagnosis breast cancer Metastatic advance stage breast cancer Prior treatment least one three line biologic and/or chemotherapy metastatic breast cancer ( exclude hormonal therapy ) Patients HER2+ disease must receive prior treatment Trastuzumab Patients ER and/or PR+ disease must receive prior treatment hormonal therapy Off cytotoxic chemotherapy biologic therapy ( exclude Hormonal therapy ) ≥ 3 week Measurable disease RECIST 1.1 Central nervous system metastasis permit treat radiographically clinically stable least 4 week prior first dose STA9090 Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Life expectancy least 3 month Adequate hematologic function define : Absolute neutrophil count ≥1,500 cells/μL Platelets ≥100,000/μL Hemoglobin ≥ 9.0g/dL Adequate hepatic function define : Serum bilirubin ≤ 1.5 X upper limit normal ( ULN ) ; Adequate renal function define serum creatinine ≤ 1.5 x ULN AST , ALT , alkaline phosphatase ≤ 3 × ULN except : Patients hepatic metastasis : ALT AST ≤ 5 × ULN Patients hepatic and/or bone metastasis : alkaline phosphatase ≤ 5 × ULN Patients Gilbert 's disease : serum bilirubin &lt; 5 mg/dL Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure Female subject childbearing potential male must agree use adequate contraception ( e.g. , hormonal barrier method birth control ; abstinence ) duration study treatment Female subject childbearing age must negative serum pregnancy test study entry . Surgery , radiotherapy , lesion ablative procedure area measurable disease Major surgery within 4 week prior first dose STA9090 Poor peripheral venous access study drug administration . Study drug administration via indwell catheter allow catheter make silicone material . History severe ( grade 3 4 ) allergic hypersensitivity reaction excipients ( e.g. , Polyethylene glycol [ PEG ] 300 Polysorbate 80 ) Baseline QTc &gt; 470 msec Ventricular ejection fraction ( EF ) &lt; 50 % baseline Treatment chronic immunosuppressant ( e.g. , cyclosporine follow transplantation ) Women pregnant lactating Uncontrolled intercurrent illness include , limited , human immunodeficiency virus ( HIV ) positive subject receive combination antiretroviral therapy , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , ventricular arrhythmia , psychiatric illness/social situation would limit compliance study requirement Other medication , severe acute/chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result judgment investigator Seizure disorder requirement seizure medication Prior treatment HSP90 inhibitor persistent adverse event prior therapy &gt; 1 grade 1 severity history current coronary artery disease , myocardial infarction , angina pectoris , angioplasty coronary bypass surgery history current uncontrolled dysrhythmias , requirement antiarrhythmic medication , Grade 2 great leave bundle branch block New York Heart Association class II/III/IV congestive heart failure history dyspnea , orthopnea , edema require current treatment angiotensin convert enzyme inhibitor , angiotensin II receptor blocker , beta blocker diuretic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>STA-9090</keyword>
	<keyword>advanced breast cancer</keyword>
	<keyword>10-145</keyword>
</DOC>